PLYX
Income statement / Annual
Last year (2024), Polaryx Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Polaryx Therapeutics Inc.'s net income was -$30.36 M.
See Polaryx Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
| Period Ended |
12/31/2024 |
12/31/2023 |
| Operating Revenue |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
| Research and Development Expenses |
$2.81 M
|
$2.77 M
|
| General & Administrative Expenses |
$1.54 M
|
$1.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.54 M
|
$1.01 M
|
| Other Expenses |
$0.00
|
$0.00
|
| Operating Expenses |
$4.35 M
|
$3.78 M
|
| Cost And Expenses |
$4.35 M
|
$3.78 M
|
| Interest Income |
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
| EBITDA |
-$4.35 M |
-$3.78 M |
| EBITDA Ratio |
0
|
0
|
| Operating Income Ratio |
0
|
0
|
| Total Other Income/Expenses Net |
-$26.00 M
|
$2.00 K
|
| Income Before Tax |
-$30.36 M
|
-$3.78 M
|
| Income Before Tax Ratio |
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
| Net Income |
-$30.36 M
|
-$3.78 M
|
| Net Income Ratio |
0
|
0
|
| EPS |
-0.16 |
-0.02 |
| EPS Diluted |
-0.16 |
-0.02 |
| Weighted Average Shares Out |
$189.37 M
|
$189.37 M
|
| Weighted Average Shares Out Diluted |
$189.37 M
|
$189.37 M
|
| Link |
|
|
